Platelet level as a new prognostic factor for idiopathic pulmonary arterial hypertension in the era of combination therapy

Hiroki Taguchi, Masaharu Kataoka, Ryoji Yanagisawa, Takashi Kawakami, Yuichi Tamura, Keiichi Fukuda, Hideaki Yoshino, Toru Satoh

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: The recent development of various effective drugs, such as epoprostenol, sildenafil, and bosentan, has improved the prognosis for patients with idiopathic pulmonary arterial hypertension (IPAH). This study sought to determine survival rates and to identify predictive prognostic factors in patients with IPAH in the current era of combination therapy with new and more effective vasodilators. Methods and Results: In 65 consecutive IPAH patients treated from 2004 to 2009, hemodynamic parameters were significantly improved and brain natriuretic peptide was significantly decreased by combination therapy (observation period: 35±18 months). The Kaplan-Meier survival curves were determined, and 22 prognostic variables, including 9 hemodynamic variables and 6 biomarkers, were evaluated to obtain the best variables. The 1-year and 3-year survival rates were 98% and 86%, respectively. Only the platelet level was correlated with death (P<0.05), and the platelet level was significantly correlated with mean pulmonary arterial pressure (P<0.01). Patients with a lower platelet level (<20+10 4/μl (median value)) before treatment had a higher mortality rate compared to the other patients (78% vs. 95% for 3-year survival, P<0.01). Conclusions: Combination therapy contributed to an improvement in the prognosis of IPAH patients. Platelet level is a significant prognostic predictor in this new treatment era.

Original languageEnglish
Pages (from-to)1494-1500
Number of pages7
JournalCirculation Journal
Volume76
Issue number6
DOIs
Publication statusPublished - 2012 Jun

Fingerprint

Blood Platelets
Therapeutics
Survival Rate
Hemodynamics
Brain Natriuretic Peptide
Kaplan-Meier Estimate
Epoprostenol
Vasodilator Agents
Familial Primary Pulmonary Hypertension
Arterial Pressure
Biomarkers
Observation
Lung
Survival
Mortality
Pharmaceutical Preparations

Keywords

  • Combination therapy
  • Idiopathic pulmonary arterial hypertension
  • Platelet
  • Prognostic factor
  • Survival

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Platelet level as a new prognostic factor for idiopathic pulmonary arterial hypertension in the era of combination therapy. / Taguchi, Hiroki; Kataoka, Masaharu; Yanagisawa, Ryoji; Kawakami, Takashi; Tamura, Yuichi; Fukuda, Keiichi; Yoshino, Hideaki; Satoh, Toru.

In: Circulation Journal, Vol. 76, No. 6, 06.2012, p. 1494-1500.

Research output: Contribution to journalArticle

Taguchi, Hiroki ; Kataoka, Masaharu ; Yanagisawa, Ryoji ; Kawakami, Takashi ; Tamura, Yuichi ; Fukuda, Keiichi ; Yoshino, Hideaki ; Satoh, Toru. / Platelet level as a new prognostic factor for idiopathic pulmonary arterial hypertension in the era of combination therapy. In: Circulation Journal. 2012 ; Vol. 76, No. 6. pp. 1494-1500.
@article{0f657bb6213e45ad877283682ed7a86d,
title = "Platelet level as a new prognostic factor for idiopathic pulmonary arterial hypertension in the era of combination therapy",
abstract = "Background: The recent development of various effective drugs, such as epoprostenol, sildenafil, and bosentan, has improved the prognosis for patients with idiopathic pulmonary arterial hypertension (IPAH). This study sought to determine survival rates and to identify predictive prognostic factors in patients with IPAH in the current era of combination therapy with new and more effective vasodilators. Methods and Results: In 65 consecutive IPAH patients treated from 2004 to 2009, hemodynamic parameters were significantly improved and brain natriuretic peptide was significantly decreased by combination therapy (observation period: 35±18 months). The Kaplan-Meier survival curves were determined, and 22 prognostic variables, including 9 hemodynamic variables and 6 biomarkers, were evaluated to obtain the best variables. The 1-year and 3-year survival rates were 98{\%} and 86{\%}, respectively. Only the platelet level was correlated with death (P<0.05), and the platelet level was significantly correlated with mean pulmonary arterial pressure (P<0.01). Patients with a lower platelet level (<20+10 4/μl (median value)) before treatment had a higher mortality rate compared to the other patients (78{\%} vs. 95{\%} for 3-year survival, P<0.01). Conclusions: Combination therapy contributed to an improvement in the prognosis of IPAH patients. Platelet level is a significant prognostic predictor in this new treatment era.",
keywords = "Combination therapy, Idiopathic pulmonary arterial hypertension, Platelet, Prognostic factor, Survival",
author = "Hiroki Taguchi and Masaharu Kataoka and Ryoji Yanagisawa and Takashi Kawakami and Yuichi Tamura and Keiichi Fukuda and Hideaki Yoshino and Toru Satoh",
year = "2012",
month = "6",
doi = "10.1253/circj.CJ-11-1223",
language = "English",
volume = "76",
pages = "1494--1500",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "6",

}

TY - JOUR

T1 - Platelet level as a new prognostic factor for idiopathic pulmonary arterial hypertension in the era of combination therapy

AU - Taguchi, Hiroki

AU - Kataoka, Masaharu

AU - Yanagisawa, Ryoji

AU - Kawakami, Takashi

AU - Tamura, Yuichi

AU - Fukuda, Keiichi

AU - Yoshino, Hideaki

AU - Satoh, Toru

PY - 2012/6

Y1 - 2012/6

N2 - Background: The recent development of various effective drugs, such as epoprostenol, sildenafil, and bosentan, has improved the prognosis for patients with idiopathic pulmonary arterial hypertension (IPAH). This study sought to determine survival rates and to identify predictive prognostic factors in patients with IPAH in the current era of combination therapy with new and more effective vasodilators. Methods and Results: In 65 consecutive IPAH patients treated from 2004 to 2009, hemodynamic parameters were significantly improved and brain natriuretic peptide was significantly decreased by combination therapy (observation period: 35±18 months). The Kaplan-Meier survival curves were determined, and 22 prognostic variables, including 9 hemodynamic variables and 6 biomarkers, were evaluated to obtain the best variables. The 1-year and 3-year survival rates were 98% and 86%, respectively. Only the platelet level was correlated with death (P<0.05), and the platelet level was significantly correlated with mean pulmonary arterial pressure (P<0.01). Patients with a lower platelet level (<20+10 4/μl (median value)) before treatment had a higher mortality rate compared to the other patients (78% vs. 95% for 3-year survival, P<0.01). Conclusions: Combination therapy contributed to an improvement in the prognosis of IPAH patients. Platelet level is a significant prognostic predictor in this new treatment era.

AB - Background: The recent development of various effective drugs, such as epoprostenol, sildenafil, and bosentan, has improved the prognosis for patients with idiopathic pulmonary arterial hypertension (IPAH). This study sought to determine survival rates and to identify predictive prognostic factors in patients with IPAH in the current era of combination therapy with new and more effective vasodilators. Methods and Results: In 65 consecutive IPAH patients treated from 2004 to 2009, hemodynamic parameters were significantly improved and brain natriuretic peptide was significantly decreased by combination therapy (observation period: 35±18 months). The Kaplan-Meier survival curves were determined, and 22 prognostic variables, including 9 hemodynamic variables and 6 biomarkers, were evaluated to obtain the best variables. The 1-year and 3-year survival rates were 98% and 86%, respectively. Only the platelet level was correlated with death (P<0.05), and the platelet level was significantly correlated with mean pulmonary arterial pressure (P<0.01). Patients with a lower platelet level (<20+10 4/μl (median value)) before treatment had a higher mortality rate compared to the other patients (78% vs. 95% for 3-year survival, P<0.01). Conclusions: Combination therapy contributed to an improvement in the prognosis of IPAH patients. Platelet level is a significant prognostic predictor in this new treatment era.

KW - Combination therapy

KW - Idiopathic pulmonary arterial hypertension

KW - Platelet

KW - Prognostic factor

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84861600499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861600499&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-11-1223

DO - 10.1253/circj.CJ-11-1223

M3 - Article

C2 - 22447010

AN - SCOPUS:84861600499

VL - 76

SP - 1494

EP - 1500

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 6

ER -